Molbio Diagnostics is set for a significant stock market debut following a robust IPO subscription of 70 times. With a promising grey market premium suggesting a 19.3% rise over its issue price, investors are eagerly awaiting Monday’s listing on the NSE and BSE.Molbio Diagnostics is set for a significant stock market debut following a robust IPO subscription of 70 times. With a promising grey market premium suggesting a 19.3% rise over its issue price, investors are eagerly awaiting Monday’s listing on the NSE and BSE.Â
Your trusted source for real-time market insights, expert analysis, and breaking financial news. We deliver actionable updates on global markets, stocks, crypto, and economic trends empowering investors to make informed decisions every day.
Contact us: contact@financeworld-news.com
© Copyright 2025 - financeworld-news.com